ZA200800116B - New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis - Google Patents

New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis

Info

Publication number
ZA200800116B
ZA200800116B ZA200800116A ZA200800116A ZA200800116B ZA 200800116 B ZA200800116 B ZA 200800116B ZA 200800116 A ZA200800116 A ZA 200800116A ZA 200800116 A ZA200800116 A ZA 200800116A ZA 200800116 B ZA200800116 B ZA 200800116B
Authority
ZA
South Africa
Prior art keywords
fibrotic
liver fibrosis
new combination
caspase inhibitor
madcam antibody
Prior art date
Application number
ZA200800116A
Other languages
English (en)
Inventor
Burgess Gary Craig
Kerry Roger
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ZA200800116B publication Critical patent/ZA200800116B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
ZA200800116A 2005-07-11 2008-01-04 New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis ZA200800116B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69856105P 2005-07-11 2005-07-11

Publications (1)

Publication Number Publication Date
ZA200800116B true ZA200800116B (en) 2008-12-31

Family

ID=37434222

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800116A ZA200800116B (en) 2005-07-11 2008-01-04 New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis

Country Status (15)

Country Link
US (1) US20090214527A1 (zh)
EP (1) EP1904100A1 (zh)
JP (1) JP2007023030A (zh)
KR (1) KR20080017094A (zh)
CN (1) CN101217980A (zh)
AR (1) AR054828A1 (zh)
AU (1) AU2006267976B2 (zh)
BR (1) BRPI0613459A2 (zh)
CA (1) CA2614622A1 (zh)
IL (1) IL188397A0 (zh)
MX (1) MX2008000659A (zh)
RU (1) RU2008101383A (zh)
TW (1) TW200730190A (zh)
WO (1) WO2007007162A1 (zh)
ZA (1) ZA200800116B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2552523C (en) * 2004-01-09 2019-11-26 Pfizer Inc. Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
US20080070823A1 (en) * 2006-09-15 2008-03-20 Philip Gorlin Liquid Detergent Composition
CA2669849C (en) * 2006-12-06 2012-01-31 Pfizer Inc. Crystalline forms of (3s)-3-[n-(n'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
AU2009292959B2 (en) 2008-09-19 2016-02-25 Henry Ford Health System Methods, systems, and compositions for calpain inhibition
WO2012021800A2 (en) * 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
CN108884045B (zh) 2016-05-11 2020-12-04 正大天晴药业集团股份有限公司 Caspase抑制剂及其药物组合物、用途和治疗方法
JP7160491B2 (ja) 2017-07-14 2022-10-25 ファイザー インコーポレイティッド ＭＡｄＣＡＭに対する抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2004081049A1 (en) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
CA2552523C (en) * 2004-01-09 2019-11-26 Pfizer Inc. Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
ATE483732T1 (de) * 2005-07-08 2010-10-15 Pfizer Ltd Madcam-antikörper

Also Published As

Publication number Publication date
EP1904100A1 (en) 2008-04-02
KR20080017094A (ko) 2008-02-25
BRPI0613459A2 (pt) 2011-01-11
IL188397A0 (en) 2008-08-07
RU2008101383A (ru) 2009-07-20
AU2006267976B2 (en) 2009-12-24
AR054828A1 (es) 2007-07-18
MX2008000659A (es) 2008-03-13
TW200730190A (en) 2007-08-16
CA2614622A1 (en) 2007-01-18
WO2007007162A1 (en) 2007-01-18
CN101217980A (zh) 2008-07-09
JP2007023030A (ja) 2007-02-01
AU2006267976A1 (en) 2007-01-18
US20090214527A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
ZA200800116B (en) New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis
EP1883406A4 (en) COMPOSITIONS AND METHOD FOR CONTINUOUS RELEASE OF BETA-ALLANINE
ZA200802490B (en) Isoindole-imide compounds and compositions comprising and methods of using the same
IL185914A0 (en) Pyrimidine compounds and methods of use
BRPI0615224A2 (pt) redução de esteróis e de outros compostos em óleos
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
EP1940787A4 (en) NOVEL IDO INHIBITORS AND METHODS OF USE
IL191072A0 (en) Therapeutic compositions and methods
EP1951278A4 (en) METHODS AND COMPOSITIONS FOR DEREPRESSION OF IPA-INHIBITED CASPASE
IL187304A0 (en) Pyrrolopyridine - based inhibitors of dipeptidyl peptidase iv and methods
HK1135099A1 (en) Aza-indolyl compounds and methods of use
ZA200805296B (en) Allergy inhibitor compositions and kits and methods of using the same
IL182943A0 (en) Ovr110 antibody compositions and methods of use
HK1099757A1 (en) Caspase inhibitors and uses thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1763346A4 (en) COMPOSITION AND METHODS RELATING TO INHIBITORS OF PYRIMIDINE SYNTHESIS
EP1937075A4 (en) SYNERGIC COMPOSITION AND METHOD OF USE
EP1933805A4 (en) INFLAMMATORY COMPOSITIONS AND METHODS OF ADMINISTRATION
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP1912630A4 (en) COMPOSITIONS AND METHODS FOR REDUCING POSTOPERATIVE PAIN
PT2572724T (pt) Tratamento de fibroses e doenças hepáticas
EP1940458A4 (en) COMPOSITIONS AND METHODS OF INHIBITING GRANZYME B
EP1912633A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING VASCULAR PERMEABILITY
EP1887002A4 (en) CARBOXYLIC AMIDE COMPOUND AND USE THEREOF